JP2017535261A5
(OSRAM )
2018-11-15
JP2017533706A5
(OSRAM )
2018-12-06
Vivier et al.
2024
Natural killer cell therapies
Manier et al.
2022
Current state and next-generation CAR-T cells in multiple myeloma
AU2019222550B2
(en )
2022-10-27
Modified pluripotent stem cells and methods of making and use
JP7146397B2
(ja )
2022-10-04
改変γδＴ細胞
Butler et al.
2014
Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy
Batlevi et al.
2016
Novel immunotherapies in lymphoid malignancies
JP2017533707A5
(OSRAM )
2018-12-06
Dianat‐Moghadam et al.
2019
Natural killer cell–based immunotherapy: From transplantation toward targeting cancer stem cells
Cerwenka et al.
2016
Natural killer cell memory in infection, inflammation and cancer
Kohn et al.
2011
CARs on Track in the Clinic: Workshop of the Blood and Marrow Transplant Clinical Trials Network Subcommittee on Cell and Gene Therapy Washington DC, 18 May 2010
JP2019513347A5
(OSRAM )
2020-04-16
Dai et al.
2020
4-1BB signaling boosts the anti-tumor activity of CD28-incorporated 2nd generation chimeric antigen receptor-modified T cells
Shi et al.
2013
Improving the efficacy and safety of engineered T cell therapy for cancer
JP2018504910A5
(OSRAM )
2018-12-06
AU2019202514A1
(en )
2019-05-02
Chimeric antigen receptors and methods of making
JP2020513839A5
(OSRAM )
2021-02-25
Reindl et al.
2020
Immunotherapy with NK cells: recent developments in gene modification open up new avenues
JPWO2020047452A5
(OSRAM )
2022-09-06
JP2021501604A5
(OSRAM )
2021-12-09
JP2020506700A5
(OSRAM )
2021-03-11
EP3454870A1
(en )
2019-03-20
Methods for selective expansion of gamma delta t-cell populations and compositions thereof
Geldres et al.
2016
Chimeric antigen receptor-redirected T cells return to the bench
JP2015527070A5
(OSRAM )
2016-12-08